DPP4 and type 2 diabetes mellitus: Six statements did not reach consensus: IFG guiding the choice of therapy or being an indication for the addition of PEGV, the need to refer acromegalic diabetic patients to a Diabetology center, the consideration on the use of DPP-4 inhibitors or GLP-1 receptor agonists in a controlled patient, and the influence of T2DM in the therapy choice in case of fgSRL resistance or the necessity to add PEGV in such patients.